Alemtuzumab Is The Most Cost-Effective Option In Comparison To Available Therapies In The Treatment of Rrms From The UK NHS Perspective
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.1945
https://www.valueinhealthjournal.com/article/S1098-3015(17)32279-9/fulltext
Title :
Alemtuzumab Is The Most Cost-Effective Option In Comparison To Available Therapies In The Treatment of Rrms From The UK NHS Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)32279-9&doi=10.1016/j.jval.2017.08.1945
First page :
A723
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1776